Dermatology

Savanna Perry, PA-C, founder of The PA Platform, discusses the strategies and goals that go into building an online audience as a healthcare professional.

New phase 3 extension data show the topical PDE-4 inhibitor provided skin clearance to a significant rate of patients with psoriasis.

Though previous research had demonstrated an increased risk of MetS in patients with psoriasis, this study was first to consider the prevalence of the condition a global scale.

Dr. Brown and Mr. Zavodnick speak on the first and only FDA-approved steroid-free topical medication in its class approved for psoriasis, and the data that bolstered this approval.

Investigators observed that patients with quantifiable levels of brodalumab following 12 weeks of therapy experienced significantly higher PASI reductions that those without.

Exact triggers in acute urticaria and chronic urticaria are largely unknown, with the success of identifying causes of AU varying between 21-68%.

Previous research has suggested that psoriasis could affect both fecundity and fertility, leading to spontaneous abortion and ectopic pregnancy.

The current registered dosing of the therapy is 30 mg twice daily, but the analyzed dosage of 20 mg has not yet been approved.

Similarly, patients affected by alopecia areata had higher odds of developing psoriasis.

New 5-year data shows psoriasis improvement was similar among patients with and without metabolic syndrome, regardless of which dose they received.

However, comorbidity risk was believed to be substantially different between the two diseases.

EPSOLAY is the first and only micro-encapsulated benzoyl peroxide topical treatment shown to improve inflammatory lesions associated with rosacea

Double board certified dermatologist Dr. Karan Lal details targeted therapies and surgical treatments for vitiligo and how the condition is perceived by different cultures.

Dr. Brett King returns to discuss the impact of JAK inhibitors in the management of atopic dermatitis.

Dr. Sarah Asch details therapeutic strategies for treating pediatric patients with vitiligo.

Key themes such as a distrust in conventional therapies and non-conventional "cures" with no scientific evidence were observed.

Cotton gloves showed superior comfort and practicability among patients with hand dermatoses.

Despite this, investigators noted that patients with ICI-induced bullous pemphigoids experienced relatively improved tumor responses.

The study suggested that dermatologists in academic settings were more likely to utilize teledermatology prior to the limitations of the COVID-19 pandemic as well.

New phase 3 data found that 70% of patients with atopic dermatitis achieved EASI-75 following treatment with lebrikizumab and topical corticosteroids

A new systematic review found that patients with the dermatologic condition experienced moderate impairment of health-related quality of life and emotions.

Conversely, age was shown to have a negative association, as did the highest category of physical activity.

Botulin toxin was first approved by the FDA in 2002 for cosmetic reasons.

Differences in rosacea subtypes were also observed regarding patient sex, continent of origin, and the year of publication.

In data presented at AAD, investigators found increased odds of GERD in patients with rosacea compared to a control group without rosacea.